Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | LAP3 | P28838 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10710883 | 1.00 | SLC7A5 (0.46) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL288204 | 0.92 | SLC7A5 (0.52) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL10530419 | 0.92 | SLC7A5 (0.52) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL709252 | 0.87 | SLC7A5 (0.36) | SLC7A5DPP4SMN1; SMN2SLC1A3SLC1A2 | |
| SCHEMBL866414 | 0.87 | SLC7A5 (0.36) | SLC7A5DPP4SMN1; SMN2SLC1A3SLC1A2 | |
| SCHEMBL17222464 | 0.87 | SLC7A5 (0.36) | SLC7A5DPP4SMN1; SMN2SLC1A3SLC1A2 | |
| SCHEMBL2027762 | 0.87 | SLC7A5 (0.36) | SLC7A5DPP4SMN1; SMN2SLC1A3SLC1A2 | |
| SCHEMBL6536106 | 0.87 | SLC7A5 (0.36) | SLC7A5DPP4SMN1; SMN2SLC1A3SLC1A2 | |
| SCHEMBL3191865 | 0.83 | SLC7A5 (0.33) | SLC7A5 | |
| SCHEMBL1421759 | 0.83 | SLC7A5 (0.44) | SLC7A5DPP4FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 632 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240196946-A1 | METABOLICALLY MODIFIED VANILLA BEANS AND METHODS FOR PRODUCING SAME | VANILLA TECHNOLOGIES LTD. (IL) | 2024-06-20 | — | — | US | claimed |
| EP-4287847-A1 | METABOLICALLY MODIFIED VANILLA BEANS AND METHODS FOR PRODUCING SAME | Vanilla Technologies Ltd. (IL) | 2023-12-13 | — | — | EP | claimed |
| CN-117062541-A | Metabolically modified vanilla beans and method for producing same | 香草技术有限公司 | 2023-11-14 | — | — | CN | claimed |
| WO-2021151891-A1 | NOVEL PHYTOENE DESATURASE VARIANTS TO PRODUCE NEUROSPORENE AND/OR ZETA-CAROTENE | DEINOVE (FR) | 2021-08-05 | — | — | WO | claimed |
| US-20180104321-A1 | NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR | Autolus Limited (GB) | 2018-04-19 | — | — | US | claimed |
| US-9005575-B2 | Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same | STC.UNM (US) | 2015-04-14 | — | — | US | claimed |
| US-20120177722-A1 | Lyaseenzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them | VERENIUM CORPORATION | 2012-07-12 | — | — | US | claimed |
| US-7163814-B2 | Modified reductase and its gene, and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-01-16 | — | — | US | claimed |
| EP-1292615-B1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH CORP (US) | 2006-10-25 | — | — | EP | claimed |
| US-6664066-B2 | Mutant measles virus V protein; gene expression and engineering | WYETH HOLDINGS CORPORATION | 2003-12-16 | — | — | US | claimed |
| US-20030206925-A1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH HOLDINGS CORPORATION | 2003-11-06 | — | — | US | claimed |
| JP-60083580-A | — | — | None | — | — | JP | disclosed |
| WO-2025054560-A2 | ANTIBODY-DRUG CONJUGATES | NEXTPOINT THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-117903324-B | Pharmaceutical preparation for targeted degradation of hepatitis B virus X protein and application thereof | 珠海市人民医院 | 2024-07-23 | — | — | CN | disclosed |
| CN-110352074-B | Cysteine mutant antibodies for conjugation | 思进股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-1992011850-A2 | USE OF CALPAIN INHIBITORS IN THE INHIBITION AND TREATMENT OF NEURODEGENERATION | CORTEX PHARMACEUTICALS, INC. (US) | 1992-07-23 | — | — | WO | disclosed |
| US-4959314-A | MUTANTS OF ACTIVE PROTEINS, REPLACING CYSTEINE | CETUS CORPORATION (US) | 1990-09-25 | — | — | US | disclosed |
| US-4874744-A | TOPICAL APPLICATION | UNIVERSITY OF CINCINNATI (US) | 1989-10-17 | — | — | US | disclosed |
| JP-S6083580-A | METHOD FOR CULTIVATING BACTERIUM OF GENUS PSEUDOMONAS | YAMADA HIDEAKI | 1985-05-11 | — | — | JP | disclosed |
| JP-S0683580-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120177722-A1 | Lyaseenzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them | MTR, HMBS, AMPD1 | SLC7A5 935/4885DPP4 1063/4885FAP 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.